A total of 211 patients with breast cancer were enrolled in this study, patients with pCR accounted for 39.35% (61/155) and 37.50% (21/56) of the training and validation sets, respectively, the findings on HER2 was significantly correlated with the pCR status in both the training and validation set (p < 0.05). The gene discussed is ERBB2; the disease is breast cancer.